ALK and non-small cell lung carcinoma: The ATOMIC ARI-AT-002 trial (NCT02706626) is ongoing to evaluate the efficacy of brigatinib against ALK-resistant mutations after second-generation ALK inhibitor treatment other than brigatinib in patients with ALK+ NSCLC (67).